CutisPharma confirms FDA’s sanction of FIRVANQ for Clostridium difficile
U.S FDA has sanctioned CutisPharma's FIRVANQ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by …
Read More...
Read More...